News on this topic
Similar to This
GSK won U.S. approval for its second lung cancer drug from the Nuvalent ...
GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal: The FDA granted accelerated approval to neladalkib, sold as Nelkarmi ...
qz.com/gsk-neladalkib-nelkarmi-fda-approval-nuvalent-111726
China's Biotech Powerhouse 25
China's Biotech Powerhouse 25: New Chinese biotechnology index for pharma execs and life science investors, China’s Biotech Powerhouse 25 ...
statnews.com/china-biotech-index-powerhouse-25/
Steps for Personalized and Collaborative Decision-Making in HER2-Mutated ...
Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC: Get the latest updates on HER2-mutated NSCLC.
medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur
What’s Keytruda, the best-selling drug that treats 22 cancers ...
What’s Keytruda, the best-selling drug that treats 22 cancers, but is unaffordable for most?
firstpost.com/health/keytruda-cancer-drug-unaffordable-patent-14000295.html
Local consolidation therapy improves results of TKI therapy in ...
Local consolidation therapy improves results of TKI therapy in EGFR-mutated NSCLC - | German Medical Journal
aerzteblatt.de/news/lokale-konsolidierungstherapie-verbessert-ergebnisse-der-tki-therapie-beim-egfr-mutierten-nsclc-140649b8-fb72-421e-9b27-24d8ed0c662d
Good results for antibody-toxin conjugate in refractory EGFR-mutated NSCLC ...
Good results for antibody-toxin conjugate in refractory EGFR-mutated NSCLC – Deutsches Ärzteblatt
aerzteblatt.de/news/gute-ergebnisse-fur-antikorper-toxin-konjugat-beim-refraktaren-egfr-mutierten-nsclc-6da097b5-e15e-42a6-82a7-1c542f1080af
HER2-mutated NSCLC: New tyrosine kinase inhibitors with promising efficacy ...
HER2-mutated NSCLC: New tyrosine kinase inhibitors with promising efficacy – Deutsches Ärzteblatt
aerzteblatt.de/news/her2-mutiertes-nsclc-neue-tyrosinkinase-inhibitoren-mit-vielversprechender-wirksamkeit-5b11d7fb-9745-4320-9a49-f855c962f51d
Uncovering new therapeutic targets for a common KRAS mutation behind ...
Uncovering new therapeutic targets for a common KRAS mutation behind cancer: A team of Northwestern investigators has discovered novel molecular underpinnings of ...
medicalxpress.com/news/2025-10-uncovering-therapeutic-common-kras-mutation.html
US approves AstraZeneca, Daiichi's treatment for lung cancer
US approves AstraZeneca, Daiichi's treatment for lung cancer: Pharma Breakthrough: AstraZeneca and Daiichi's Datroway gets US FDA approval for advanced ...
deccanherald.com/world/us-approves-astrazeneca-daiichis-treatment-for-lung-cancer-3600115
AstraZeneca gets CDSCO nod for lung cancer drug
AstraZeneca gets CDSCO nod for lung cancer drug: Pharma Breakthrough Oncology India: CDSCO approves AstraZeneca’s Osimertinib for locally advanced ...
deccanherald.com/health/astrazeneca-gets-cdsco-nod-for-lung-cancer-drug-3562420